



PROVIDING ANSWERS FOR CANCER PATIENTS

**Press release**

**21 May, 2021**

## **Curasight presents at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik**

Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik.

The presentation will be webcasted live 10:55 (CET), Tuesday 25 May 2021.

For more information – please [click here](#)

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO  
Phone: +45 22 83 01 60  
E-mail: [uk@curasight.com](mailto:uk@curasight.com)  
[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.